Zomedica Announces "Fourth Friday at Four" Webinar on September 25, 2026: Inside Zomedica’s Marketing Engine: How Demand Becomes Revenue

Back to the Newsroom Zomedica Announces "Fourth Friday at Four" Webinar on September 25, 2026: Inside Zomedica’s Marketing Engine: How Demand Becomes Revenue Wednesday, 09 September 2026 06:00 AM Topic: Company Update September session to spotlight how Zomedica's marketing function creates demand, equips the field, and supports utilization across the company's diagnostic and therapeutic portfolios ANN ARBOR, MI / ACCESS Newswire / September 9, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the next installment of its "Fourth Friday at Four" investor webinar series, scheduled for Friday, September 25, 2026, at 4:00 p.m. Eastern Time. The September program, titled "Inside Zomedica's Marketing Engine: How Demand Becomes Revenue," will give current and prospective investors a detailed look at the marketing function that sits at the front end of Zomedica's revenue engine: how the Company identifies and reaches its customers, how it creates a qualified commercial demand, how it equips its field organization, and how it supports adoption and utilization once a product is in the practice. The session will trace the evolution of Zomedica's marketing organization from a single-product launch in 2021, through a portfolio assembled by acquisition, to the structured upstream and downstream function operating today. Upstream marketing works alongside product development so that products are shaped around what practicing veterinarians actually need. Downstream marketing takes those products to market and keeps them selling, through targeting and positioning, sales enablement, digital systems and paid reach, continuing education of a direct customer audience, and field presence at the conferences where veterinary professionals evaluate new technology. The session is built around a central idea: Zomedica operates two product portfolios, diagnostics and therapeutics, that are sold to overlapping customers by a single marketing engine. A practice that adopts a diagnostic platform may also benefit from a therapeutic solution, while the Company's owned customer data creates opportunities to introduce complementary products that support better medicine and greater veterinary practice profitability. Larry Heaton, Chief Executive Officer of Zomedica, commented, "Marketing is where our commercial results begin, and it does far more than generate awareness. Our marketing team defines who our customers are and what our products are worth to them, builds the demand that our sales organization converts, equips our field team with the positioning and materials they need for productive conversations, and supports veterinarians well past the sale so that our platforms are used and our consumables recur. This webinar is an opportunity for investors to see how that engine is built, how it serves both of our portfolios at once, and why we believe it is a durable driver of growth." Webinar Details Title: "Fourth Friday at Four - Inside Zomedica's Marketing Engine: How Demand Becomes Revenue" Date/Time: Friday, September 25, 2026, at 4:00 p.m. Eastern Time Registration: https://itl.ink/September25 Format: Customer testimonials, prepared remarks, featured interviews with Zomedica's product marketing, digital, education and field marketing leaders, and a live Question & Answer session. Whether you're a veterinary professional, industry partner, investor, or simply passionate about helping our pets live healthier lives, this series is for you. About Zomedica Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi Loop® line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, the VetGuardian PLUS™ Zero Touch® monitoring system and VETIGEL® hemostatic gel, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 17% in 2025 to $32 million, 36% through the six months ended June 30, 2026 to $18 million, and maintains a strong balance sheet with approximately $44 million in liquidity as of June 30, 2026. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitabilit